Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

288 articles about Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

• Tenax Therapeutics to Present at Upcoming Investor Conferences

  9/20/2018

  Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market.

• Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients

  8/28/2018

  Tenax Therapeutics , Inc. (NASDAQ: TENX) today announced the results of a new study titled "Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double‐Blind Controlled Trial” were published in the August 21, 2018 issue of the Journal of the American Heart Association (

• Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO

  6/5/2018

  Tenax Therapeutics, Inc. today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018.

• Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients

  6/1/2018

  Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction

• Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients

  4/4/2018

  FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction

• Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

  3/14/2018

  Tenax has regained compliance with the Bid Price Rule and the matter is now closed.

• Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension

  3/1/2018

  Preclinical studies find levosimendan improves right heart function; Beneficial treatment for right heart failure secondary to pulmonary hypertension

• World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase II Study

  2/6/2018

  Tenax Therapeutics announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF.

• Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies

  1/16/2018

  Tenax announced plans to advance the development of levosimendan for the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF).

• Tenax Therapeutics Provides Regulatory Update On Levosimendan

  7/31/2017

• Tenax Therapeutics Meets With FDA To Discuss Positive Mortality Data And Potential Levosimendan NDA Submission

  5/17/2017

• Tenax Therapeutics CEO Steps Down, Company to Review Strategic Alternatives

  4/6/2017

• Tenax Therapeutics Announces Year-End 2016 Financial Results And Provides Corporate Update

  3/21/2017

• Tenax Therapeutics To Discuss Year-End 2016 Financial Results And Provide Business Update

  3/16/2017

• Tenax Therapeutics's Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint

  1/31/2017

• Tenax Therapeutics Announces Completion Of Enrollment For Phase III LEVO-CTS Trial In Cardiac Surgery

  11/18/2016

• Tenax Therapeutics Announces Third Quarter 2016 Financial Results And Provides Corporate Update

  11/10/2016

• Tenax Therapeutics To Discuss Third Quarter 2016 Financial Results And Provide Business Update

  11/4/2016

• Tenax Therapeutics Provides Clinical Update For Lead Candidate Levosimendan

  10/5/2016

• Tenax Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update

  8/11/2016